FULGENT GENETICS, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
FULGENT GENETICS, INC. (FLGT) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-07-30
- 2026-06-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month $0.00.
- 2025-06-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month $9.93M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 |
| 2025-06-30 | $9.93M 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |